-
Pramlintide
- indication:For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
- pharmacologypharmacology:
- mechanism: Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.
- toxicity:
- absorprion: The absolute bioavailability of a single subcutaneous dose of pramlintide is approximately 30 to 40%.
- halflife: Approximately 48 minutes
- roouteelimination: Pramlintide is metabolized primarily by the kidneys.
- volumedistribution:
- clearance: